Literature DB >> 25638628

Early experience of the use of fibrin sealant in the management of children with pilonidal sinus disease.

Caroline Mary Smith1, Abigail Jones1, Dipankar Dass1, Govind Murthi1, Richard Lindley2.   

Abstract

BACKGROUND: The use of fibrin sealant in the management of pilonidal sinus disease has not previously been described in children. We present our experience of primary pit excision and use of fibrin sealant (PEF) and compare outcomes with lateralising flap procedures (LFP).
METHODS: A single centre retrospective case note review of all children who had undergone a definitive procedure for pilonidal sinus from August 2006 to Dec 2013 was performed using data expressed as median (range) and compared using Fisher's exact test. P<0.05 was regarded as significant.
RESULTS: Forty-one children were identified having undergone 49 procedures, with median age 15 (12-16 years) and follow up 32 (8-92) months. Groups were comparable for disease severity. Ten children underwent primary PEF and twenty-six LFP. Two children had recurrence following primary PEF and had repeat PEF which was curative. Overall recurrence rates following PEF procedure were comparable to LFP (17% vs 21%; P=1.0). There were no wound dehiscences in the PEF group and one wound infection. There was one wound dehiscence and one wound infection in the LFP group. Median operative time for PEF was lower than LFP (20 vs 60 min, P=0.001). 83% of PEF procedures were performed as day cases. One child was lost to follow up, and two children progressed to adult services.
CONCLUSIONS: We recommend PEF in children with pilonidal sinus disease as primary treatment and for recurrence. PEF has comparable recurrence and wound infection rates to LFPs, is performed as day case, has shorter anaesthetic times, and the risk of wound dehiscence is avoided.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibrin glue; Fibrin sealant; Pilonidal disease; Pilonidal sinus

Mesh:

Substances:

Year:  2014        PMID: 25638628     DOI: 10.1016/j.jpedsurg.2014.11.022

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Is conservative treatment an effective option for pilonidal sinus disease in children?

Authors:  Muazez Cevik; Mustafa Erman Dorterler; Latif Abbasoglu
Journal:  Int Wound J       Date:  2018-06-27       Impact factor: 3.315

2.  Fibrin glue is a quick and effective treatment for primary and recurrent pilonidal sinus disease.

Authors:  T S Sian; P J J Herrod; J E M Blackwell; E J O Hardy; J N Lund
Journal:  Tech Coloproctol       Date:  2018-11-09       Impact factor: 3.781

3.  Preliminary report on endoscopic pilonidal sinus treatment in children: results of a multicentric series.

Authors:  Alessio Pini Prato; Cinzia Mazzola; Girolamo Mattioli; Maria Escolino; Ciro Esposito; Antonio D'Alessio; Laura Caterina Abati; Lorenzo Leonelli; Claudio Carlini; Franco Rotundi; Pier Carlo Meinero
Journal:  Pediatr Surg Int       Date:  2018-04-19       Impact factor: 1.827

4.  Fibrin sealant use in pilonidal sinus: Systematic review.

Authors:  Cuneyt Kayaalp; Ismail Ertugrul; Kerem Tolan; Fatih Sumer
Journal:  World J Gastrointest Surg       Date:  2016-03-27

Review 5.  Guidelines on pediatric day surgery of the Italian Societies of Pediatric Surgery (SICP) and Pediatric Anesthesiology (SARNePI).

Authors:  Ugo de Luca; Giovanni Mangia; Simonetta Tesoro; Ascanio Martino; Maria Sammartino; Alessandro Calisti
Journal:  Ital J Pediatr       Date:  2018-03-12       Impact factor: 2.638

6.  Common surgical procedures in pilonidal sinus disease: A meta-analysis, merged data analysis, and comprehensive study on recurrence.

Authors:  V K Stauffer; M M Luedi; P Kauf; M Schmid; M Diekmann; K Wieferich; B Schnüriger; D Doll
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

7.  Impact of geography and surgical approach on recurrence in global pilonidal sinus disease.

Authors:  Dietrich Doll; Andriu Orlik; Katharina Maier; Peter Kauf; Marco Schmid; Maja Diekmann; Andreas P Vogt; Verena K Stauffer; Markus M Luedi
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.